HYBRID EVENT: You can participate in person at Tokyo, Japan from your home or work.
Neuroendocrine tumors (NETs) are a rare type of neoplasm that originates in the specialized cells of the neuroendocrine system. These cells have characteristics of both nerve cells and hormone-producing endocrine cells, allowing them to release hormones into the bloodstream. NETs can develop in various organs throughout the body, with the most common sites being the gastrointestinal tract, pancreas, and lungs. The clinical presentation of NETs varies widely, and symptoms may arise from hormone overproduction or the mass effect of the tumor. The slow-growing nature of many NETs can lead to delayed diagnosis, often when the tumors have already metastasized. Treatment modalities for NETs depend on factors such as tumor grade, stage, and location. Surgical resection remains a primary option when feasible, aiming to remove the tumor and surrounding affected tissues. Additionally, medical therapies, including somatostatin analogs, targeted therapies, and peptide receptor radionuclide therapy (PRRT), play pivotal roles in managing NETs and controlling symptoms. The prognosis for individuals with NETs varies based on factors such as tumor grade, stage, and response to treatment. While some NETs exhibit indolent behavior, others may be more aggressive. Close monitoring and a multidisciplinary approach involving oncologists, surgeons, and other specialists are essential for optimal management and improved outcomes for patients with neuroendocrine tumors.
